EP 2888261 A2 20150701 - ANTAGONISTS OF CHEMOKINE RECEPTORS
Title (en)
ANTAGONISTS OF CHEMOKINE RECEPTORS
Title (de)
ANTAGONISTEN VON CHEMOKINREZEPTOREN
Title (fr)
ANTAGONISTES DES RÉCEPTEURS DE CHIMIOKINE
Publication
Application
Priority
- US 201261693758 P 20120827
- US 201361831694 P 20130606
- US 2013056796 W 20130827
Abstract (en)
[origin: US2014057937A1] Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.
IPC 8 full level
C07D 471/04 (2006.01); A61K 31/437 (2006.01); A61K 45/06 (2006.01); A61P 29/00 (2006.01); A61P 37/00 (2006.01); C07D 487/04 (2006.01); C07D 491/052 (2006.01)
CPC (source: EP RU US)
A61K 31/437 (2013.01 - RU US); A61K 31/506 (2013.01 - EP US); A61K 31/519 (2013.01 - EP RU US); A61K 45/06 (2013.01 - EP US); A61L 31/16 (2013.01 - EP US); A61P 1/04 (2018.01 - EP); A61P 9/00 (2018.01 - EP); A61P 9/10 (2018.01 - EP); A61P 11/00 (2018.01 - EP); A61P 11/06 (2018.01 - EP); A61P 17/00 (2018.01 - EP); A61P 17/06 (2018.01 - EP); A61P 19/02 (2018.01 - EP); A61P 25/00 (2018.01 - EP); A61P 25/16 (2018.01 - EP); A61P 25/28 (2018.01 - EP); A61P 29/00 (2018.01 - EP); A61P 37/00 (2018.01 - EP); A61P 37/02 (2018.01 - EP); A61P 37/06 (2018.01 - EP); A61P 37/08 (2018.01 - EP); A61P 43/00 (2018.01 - EP); C07D 471/04 (2013.01 - EP RU US); C07D 487/04 (2013.01 - EP RU US); C07D 491/052 (2013.01 - EP RU US); C07D 519/00 (2013.01 - EP US); A61L 2300/436 (2013.01 - EP US)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
US 2014057937 A1 20140227; US 9181241 B2 20151110; AU 2013308988 A1 20150312; AU 2013308988 B2 20170928; BR 112015004254 A2 20170704; CA 2883353 A1 20140306; CA 2883353 C 20200915; CN 104955454 A 20150930; CN 104955454 B 20180629; DK 2888261 T3 20180730; EP 2888261 A2 20150701; EP 2888261 A4 20160427; EP 2888261 B1 20180418; ES 2681499 T3 20180913; HK 1211588 A1 20160527; IL 237477 A0 20150430; IL 237477 B 20200730; IN 1736DEN2015 A 20150529; JP 2015530386 A 20151015; JP 6339573 B2 20180606; KR 102103188 B1 20200423; KR 20150058264 A 20150528; MX 2015002514 A 20151012; MX 367436 B 20190821; PT 2888261 T 20180725; RU 2015110982 A 20161020; RU 2646762 C2 20180307; SG 11201501479Q A 20150429; US 2016193191 A1 20160707; US 2018369213 A1 20181227; WO 2014035967 A2 20140306; WO 2014035967 A3 20150716
DOCDB simple family (application)
US 201314011174 A 20130827; AU 2013308988 A 20130827; BR 112015004254 A 20130827; CA 2883353 A 20130827; CN 201380053289 A 20130827; DK 13833111 T 20130827; EP 13833111 A 20130827; ES 13833111 T 20130827; HK 15112516 A 20151218; IL 23747715 A 20150226; IN 1736DEN2015 A 20150303; JP 2015529926 A 20130827; KR 20157008002 A 20130827; MX 2015002514 A 20130827; PT 13833111 T 20130827; RU 2015110982 A 20130827; SG 11201501479Q A 20130827; US 2013056796 W 20130827; US 201514878818 A 20151008; US 201815900405 A 20180220